Loss to follow-up in an international, multicentre observational study

作者: A Mocroft , O Kirk , P Aldins , A Chies , A Blaxhult

DOI: 10.1111/J.1468-1293.2008.00557.X

关键词:

摘要: Objective The aim of this work was to assess loss follow-up (LTFU) in EuroSIDA, an international multicentre observational cohort study. Methods LTFU defined as no visit, CD4 cell count measurement or viral load after 1 January 2006. Poisson regression used describe factors related LTFU. Results The incidence LTFU 12 304 patients 3.72 per 100 person-years [95% confidence interval (CI) 3.58–3.86; 2712 LTFU] and varied among countries from 0.67 13.35. After adjustment, older patients, those with higher counts, who had started combination antiretroviral therapy all lower incidences LTFU, while injecting drug users a LTFU. Compared Southern Europe Argentina, Eastern over twofold increased adjustment (incidence rate ratio 2.16; 95% CI 1.84–2.53; P year measured during the year; 743 (27.1%) subsequently returned follow-up. Conclusions Some thought be may have died, efforts should made ascertain vital status wherever possible. A significant proportion return follow-up.

参考文章(17)
Sean Emery, Donald I. Abrams, David A. Cooper, Janet H. Darbyshire, H.Clifford Lane, Jens D. Lundgren, James D. Neaton, The Evaluation of Subcutaneous Proleukin® (interleukin-2) in a Randomized International Trial Controlled Clinical Trials. ,vol. 23, pp. 198- 220 ,(2002) , 10.1016/S0197-2456(01)00179-9
Strategies for Management of Antiretroviral Therapy (SMART) Study Group, None, CD4+ count-guided interruption of antiretroviral treatment. The New England Journal of Medicine. ,vol. 355, pp. 2283- 2296 ,(2006) , 10.1056/NEJMOA062360
Heiko Karcher, Austin Omondi, John Odera, Andrea Kunz, Gundel Harms, Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya Tropical Medicine & International Health. ,vol. 12, pp. 687- 694 ,(2007) , 10.1111/J.1365-3156.2007.01830.X
M. Egger, B. Hirschel, P. Francioli, P. Sudre, M. Wirz, M. Flepp, M. Rickenbach, R. Malinverni, P. Vernazza, M. Battegay, Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ. ,vol. 315, pp. 1194- 1199 ,(1997) , 10.1136/BMJ.315.7117.1194
Bryan Lau, Stephen J. Gange, Richard D. Moore, Interval and Clinical Cohort Studies: Epidemiological Issues AIDS Research and Human Retroviruses. ,vol. 23, pp. 769- 776 ,(2007) , 10.1089/AID.2006.0171
Bruno Ledergerber, , Jan von Overbeck, Matthias Egger, Ruedi Lüthy, The Swiss HIV Cohort Study: Rationale, organization and selected baseline characteristics Sozial-und Praventivmedizin. ,vol. 39, pp. 387- 394 ,(1994) , 10.1007/BF01299670
S Madge, A Mocroft, D Wilson, M Youle, MCI Lipman, A Phillips, M Tyrer, A Cozzi-Lepri, L Swaden, MA Johnson, Participation in clinical studies among patients infected with HIV-1 in a single treatment centre over 12 years Hiv Medicine. ,vol. 1, pp. 212- 218 ,(2000) , 10.1046/J.1468-1293.2000.00031.X
Calvin J. Cohen, Marika K. Iwane, Jolie B. Palensky, David L. Levin, Kevin J. Meagher, Kevin R. Frost, Kenneth H. Mayer, A National HIV Community Cohort: Design, Baseline, and Follow-up of the AmFAR Observational Database Journal of Clinical Epidemiology. ,vol. 51, pp. 779- 793 ,(1998) , 10.1016/S0895-4356(98)00043-2
Allen L Gifford, William E Cunningham, Kevin C Heslin, Ron M Andersen, Terry Nakazono, Dale K Lieu, Martin F Shapiro, Samuel A Bozzette, None, Participation in research and access to experimental treatments by HIV-infected patients. The New England Journal of Medicine. ,vol. 346, pp. 1373- 1382 ,(2002) , 10.1056/NEJMSA011565
Patrice Severe, Paul Leger, Macarthur Charles, Francine Noel, Gerry Bonhomme, Gyrlande Bois, Erik George, Stefan Kenel-Pierre, Peter F. Wright, Roy Gulick, Warren D. Johnson, Jean William Pape, Daniel W. Fitzgerald, Antiretroviral Therapy in a Thousand Patients with AIDS in Haiti The New England Journal of Medicine. ,vol. 353, pp. 2325- 2334 ,(2005) , 10.1056/NEJMOA051908